Brazil and South Korea are gaining a foothold in biosimilars

Biosimilars are becoming increasingly popular with pharmaceutical companies, however, knowing which markets have been saturated with biosimilars and which are open, remains an important consideration for pharma companies, observes analytics firm GlobalData.

The firm’s healthcare analyst Lisa Maris commented: “The deal activity can provide a useful indication of which biosimilar drugs are in development. The recent strategic alliance deals show the potential of bringing these biosimilar monoclonal antibodies to market for therapy areas such as cancer or autoimmune diseases.”

Emerging markets, such as Brazil and South Korea, have been involved in a growing number of deals for the development or commercialization of biosimilars gaining a foothold for these countries in the future of the biosimilar market.